VanEck Pharmaceutical ETF (NASDAQ:PPH) Shares Bought by J.Safra Asset Management Corp

J.Safra Asset Management Corp increased its stake in VanEck Pharmaceutical ETF (NASDAQ:PPH) by 230.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 260,267 shares of the company’s stock after purchasing an additional 181,511 shares during the quarter. VanEck Pharmaceutical ETF comprises about 1.8% of J.Safra Asset Management Corp’s portfolio, making the stock its 17th biggest holding. J.Safra Asset Management Corp’s holdings in VanEck Pharmaceutical ETF were worth $22,391,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its stake in VanEck Pharmaceutical ETF by 218.3% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 21,738 shares of the company’s stock valued at $1,876,000 after purchasing an additional 14,908 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of VanEck Pharmaceutical ETF in the fourth quarter valued at $29,000. Jones Financial Companies Lllp boosted its stake in VanEck Pharmaceutical ETF by 1,827.0% during the fourth quarter. Jones Financial Companies Lllp now owns 5,704 shares of the company’s stock valued at $492,000 after buying an additional 5,408 shares in the last quarter. WT Wealth Management grew its holdings in VanEck Pharmaceutical ETF by 5.6% during the fourth quarter. WT Wealth Management now owns 56,690 shares of the company’s stock worth $4,891,000 after acquiring an additional 3,030 shares during the period. Finally, Blue Chip Partners LLC bought a new stake in VanEck Pharmaceutical ETF in the fourth quarter worth about $2,139,000.

VanEck Pharmaceutical ETF Trading Down 0.6 %

Shares of NASDAQ PPH opened at $93.99 on Wednesday. VanEck Pharmaceutical ETF has a twelve month low of $84.48 and a twelve month high of $99.51. The firm has a 50-day moving average of $88.44 and a two-hundred day moving average of $91.40. The company has a market capitalization of $586.50 million, a price-to-earnings ratio of 30.55 and a beta of 0.72.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently announced a dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 27th were paid a dividend of $0.411 per share. The ex-dividend date was Friday, December 27th. This is a positive change from VanEck Pharmaceutical ETF’s previous dividend of $0.36.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.